Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the safety of ranibizumab: a) as a surgical
adjunct during cataract surgery in subjects with proliferative diabetic retinopathy (PDR)
induced rubeosis and, b) in treatment of proliferative diabetic retinopathy (PDR).